Arcellx, Inc. (ACLX)
$115.07+0.00%Close
BUYBULL · day 46
Key stats
- Market cap
- $6.7B
- Beta
- 0.25
- P/E (TTM)
- -28.27
- 1W
- +0.02%
- 1M
- +0.22%
- vs SPY 1W
- -1.14%
- vs SPY 1M
- -2.77%
Industry peers
FMP comparable companies · ranked by market cap
- PCVXBUYVaxcyte, Inc.$10.7BRECOVERYQ 26$73.82+9.78%
- PTGXSELLProtagonist Therapeutics, Inc.$9.0BRECOVERYQ 32$140.63+2.73%
- KYMRSELLKymera Therapeutics, Inc.$9.0BBEARQ 25$109.85+2.84%
- ARWRSELLArrowhead Pharmaceuticals, Inc.$8.8BCRISISQ 12$62.35+3.31%
- ALKSSELLAlkermes plc$7.2BRECOVERYQ 6$42.76+1.25%
- IMVTSELLImmunovant, Inc.$6.9BCRISISQ 25$33.25+0.69%
- CRSPSELLCRISPR Therapeutics AG$5.5BBEARQ 20$57.34+5.85%
- AKROAkero Therapeutics, Inc.$4.5B$54.65
- VKTXSELLViking Therapeutics, Inc.$3.4BCRISISQ 22$29.28+2.81%
- NAMSSELLNewAmsterdam Pharma Company N.V.$2.7BCRISISQ 25$22.80+1.51%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on ACLX?
- LOPJLB’s latest quantitative signal on Arcellx, Inc. (ACLX) is BUY in a BULL regime. Signals are updated daily.
- What market regime is ACLX in?
- Arcellx, Inc. (ACLX) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Arcellx, Inc. (ACLX) do?
- Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multi…